Beksac, M. Et Al. 2020. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.8 .

Beksac, M., Aydin, Y., GÖKER, H., Turgut, M., BEŞIŞIK, S., Cagirgan, S., ... Tuglular, T.(2020). Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.8.

Beksac, Meral Et Al. "Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.8, 2020

Beksac, Meral Et Al. "Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.8, 2020

Beksac, M. Et Al. (2020) . "Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.8.

@article{article, author={Meral Beksac Et Al. }, title={Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2020}